The amount of accrued to related party amount.

No definition available.

Name:	abp_AccruedToAmount
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Annual sales milestone payments.

+ References

No definition available.

+ Details

Name:	abp_AnnualSalesMilestonePayments
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represent the clinical development milestones.

+ References

No definition available.

+ Details

Name:	abp_ClinicalDevelopmentMilestones
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represent the commercial sales.

+ References

No definition available.

+ Details

Name:	abp_CommercialSales
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Development milestones.

+ References

No definition available.

+ Details

Name:	abp_DevelopmentMilestones
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents milestone payment based on net sales

+ References

No definition available.

+ Details

Name:	abp_MilestonePaymentOnNetSales
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represent the milestone payment.

+ References

No definition available.

+ Details

Name:	abp_MilestonePayments
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments commercial milestones.

+ References

No definition available.

+ Details

Name:	abp_MilestonePaymentsCommercialMilestones
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents milestone payments upon achieving research and development and commercialization events.

+ References

No definition available.

+ Details

Name:	abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Net profits from licensed product sales.

+ References

No definition available.

+ Details

Name:	abp_NetProfitsFromLicensedProductSales
Namespace Prefix:	abp_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

related to the patent costs reimbursements.

+ References

No definition available.

+ Details

Name:	abp_PatentCostsReimbursements
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The company is liable for extension royalties.

+ References

No definition available.

+ Details

Name:	abp_PaymentForExtensionRoyalities
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represent the regulatory events.

+ References

No definition available.

+ Details

Name:	abp_RegulatoryEvents
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:	us-gaap_AccruedLiabilitiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 8
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-8

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.

+ References

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash paid for royalties during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ExtinguishmentOfDebtAxis=abp_OtherAccruedExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=abp_MedImmuneLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=abp_NCILicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=abp_MSKLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ExtinguishmentOfDebtAxis=us-gaap_AccountsPayableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=abp_VAZYMELicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abp_VAZYMEMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments under Research and Collaboration Agreements (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025	Dec. 31, 2024
Commitments under Research and Collaboration Agreements [Line Items]
Accrued royalties		$ 52		$ 25
Extension royalties	$ 225
Accrued extension royalties		200		200
Development milestones		32,500
Annual sales milestone payments		$ 50,000
Net profits from licensed product sales		50.00%
Accrued amount					$ 273
Other Accrued Expenses [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Patent costs reimbursements		$ 169		169
MedImmune License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments		244,000
Clinical development milestones		14,000
Regulatory events		80,000
Commercial sales		150,000
NCI License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments		3,995
Milestone payments commercial milestones		12,000
Royalties amount		25
MSK License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payment upon achieving		10,500
Milestone payment on net sales		30,000
MSK License Agreement [Member] \| Accounts Payable [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments		790		790
VAZYME License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments		200
Accrued liabilities		200		$ 200
VAZYME License Agreement [Member] \| VAZYME [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments		11,100
Minimum [Member] \| MSK License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Royalties amount		20
Maximum [Member] \| MSK License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Royalties amount		30
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpenseMember
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments		$ 70,000
Royalties amount			$ 6